ReviewBMC infectious diseases2026
Necrotizing fasciitis caused by Actinomyces europaeus: a case report and literature review.
Review in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNecrotizing fasciitis caused by Actinomyces europaeus is rare, here we report a case of necrotizing fasciitis caused by Actinomyces europaeus infection in a 43-year-old adult male from China. CASE PRESENTATION: A 43-year-old man with inguinal necrotizing fasciitis who initially received clindamycin but showed poor response. Subsequent cultures revealed polymicrobial infection, and therapy was switched to piperacillin-tazobactam with repeated surgical debridement. He was later discharged on oral amoxicillin-clavulanate for three months and fully recovered without recurrence. This case underscores the importance of early recognition, appropriate antimicrobial choice, and aggressive surgical management in Actinomyces europaeus infections. Literature review indicates that treatment duration varies with infection site and tissue vascularity, and β-lactam/β-lactamase inhibitor combinations remain the most effective option.
conclusionsEuropean actinomycosis is a rare disease, and the key to treatment is the correct application of antibiotics and effective debridement. CLINICAL TRIAL: Not applicable
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.